Leerink Partners Downgrades Celgene (CELG) to Market Perform Following Acquisition

January 3, 2019 11:56 AM

Leerink Partners analyst Geoffrey Porges downgraded Celgene (NASDAQ: CELG) from Outperform to Market Perform with a price target of $102.00 (from $112.00) following acquisition.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $66.64 yesterday.

Categories

Analyst PT Change Downgrades

Next Articles